A systematic review of the effectiveness of adalimumab

216. Schotte H, Willeke P, Mickholz E, Schorat MA,
Ortega SM, Schluter B, et al. [Long-term
treatment with etanercept significantly reduces the
production of pro-inflammatory cytokine
mononuclear cells in the blood of patients with
rheumatoid arthritis]. Z Rheumatol 2001;60:83.
217. Grigor C, Capell H, Stirling A, McMahon AD,
Lock P, Vallance R, et al. Effect of a treatment
strategy of tight control for rheumatoid arthritis
(the TICORA study): a single-blind randomised
controlled trial. Lancet 2004;364:263–9.
218. Lukina GV, Sigidin I, Skurkovich SV, Skurkovich
BS. [Double-blind trial of the effectiveness of
antibodies to interferon-gamma and tumor
necrosis factor-alpha in rheumatoid arthritis
(preliminary results)] [in Russian]. Ter Arkh 2001;
73(5):12–15.
219. Sigidin YA, Loukina GV, Skurkovich B,
Skurkovich S. Randomized, double-blind trial of
anti-interferon-gamma antibodies in rheumatoid
arthritis. Scand J Rheumatol 2001;30:203–7.
220. Brocq O, Plubel Y, Breuil V, Grisot C, Flory P,
Mousnier A, et al. Etanercept–infliximab switch in
rheumatoid arthritis 14 out of 131 patients treated
with anti TNF alpha. Presse Med 2002;31:1836–9.
221. Capria A, De Nardo D, De Sanctis G, Simonelli AR,
Kroegler B, Silvestri F, et al. Endothelial
dysfunction in rheumatoid arthritis is improved by
anti-tumor necrosis factor- treatment. European
Journal of Inflammation 2004;2:113–18.
222. Cohen JD, Zaltni S, Kaiser MJ, Bozonnat MC,
Jorgensen C, Daures JP, et al. Secondary addition
of methotrexate to partial responders to
etanercept alone is effective in severe rheumatoid
arthritis. Ann Rheum Dis 2004;63:209–10.
223. Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J,
Fabien N. Infliximab therapy in rheumatoid
arthritis and ankylosing spondylitis-induced
specific antinuclear and antiphospholipid
autoantibodies without autoimmune clinical
manifestations: a two-year prospective study.
Arthritis Res Ther 2004;6:R535–43.
224. Genovese M, Martin R, Fleischmann R,
Keystone E, Bathon J, Hinck B, et al. Etanercept
(Enbrel ® ) in early erosive rheumatoid arthritis
(ERA trial): observations at 3 years. Arthritis Rheum
2001;44(9):151.
225. Genovese MC, Martin RW, Fleischmann RM,
Keystone EC, Bathon JM, Spencer-Green G.
Etanercept (Enbrel ® ) in early erosive rheumatoid
arthritis (ERA trial): observations at 4 years.
Arthritis Rheum 2002;46(9):S530.
226. Genovese MC, Martin RW, Fleischmann RM,
Keystone EC, Bathons JM, Tsuji WH. Etanercept
(Enbrel ® ) in early erosive rheumatoid arthritis
(ERA trial): clinical and radiographic data. Arthritis
Rheum 2003;48(9 Suppl):208.
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Health Technology Assessment 2006; Vol. 10: No. 42
227. Gomez-Puerta JA, Sanmarti R, Rodriguez-Cros JR,
Canete JD. Etanercept is effective in patients with
rheumatoid arthritis with no response to
infliximab therapy. Ann Rheum Dis 2004;63:896.
228. Korczowska I, Hrycaj P, Lacki JK. Does infliximab
decrease bone turnover in rheumatoid arthritis
patients [3]. Joint Bone Spine 2003;70:398–400.
229. Kucharz EJ, Gozdzik J, Kopec M, Kotulska A,
Lewicki M, Pieczyrak R, et al. A single infusion of
infliximab increases the serum endostatin level in
patients with rheumatoid arthritis [8]. Clin Exp
Rheumatol 2003;21:273–4.
230. Osborn TG. Intraarticular etanercept versus saline
in rheumatoid arthritis: a single injection double
blind placebo controlled study. Arthritis Rheum
2002;46(9):S518.
231. Saadeh CK, Brown DM, Chumney-Malacara JM,
Crow J. Infliximab therapy for rheumatoid
arthritis (RA) induced significant control of asthma
in patients with both RA and asthma or
asthma/COPD in addition to improving RA status.
J Allergy Clin Immunol 2002;109:741.
232. Smith GR, Tymms KE, Falk M. Etanercept
treatment of renal amyloidosis complicating
rheumatoid arthritis. Intern Med J 2004;34:570–2.
233. Yazici Y, Erkan D, Kulman I, Schwartzman S,
Harrison MJ. Etanercept (ETA) vs infliximab
(INF): a comparison of efficacy in controlling
rheumatoid arthritis (RA) flares during the first
year of therapy and the year prior to their use.
Arthritis Rheum 2001;44:171.
234. Breedveld FC. Tumour necrosis factor blockade in
rheumatoid arthritis. Clin Med 2001;1:107–9.
235. Calin A. Infliximab: chimeric human–murine
monoclonal antibody. Journal of Drug Evaluation
2003;1:77–108.
236. Muhlhauser U, Munzel F, Eschenhagen T.
Etanercept. Dtsch Med Wochenschr 2003;128:1775–8.
237. Pugsley MK. Etanercept Immunex. Curr Opin
Investig Drugs 2001;2:1725–31.
238. Rashmi S, Ujala V. A novel therapeutic approach
in rheumatoid arthritis. Indian Journal of
Pharmacology 2004;36:265–6.
239. Rau R. Adalimumab (a fully human anti-tumour
necrosis factor alpha monoclonal antibody) in the
treatment of active rheumatoid arthritis: the initial
results of five trials. Ann Rheum Dis 2002;
61(Suppl 2):ii70–3.
240. Sautner J. Adalimumab (Humira) [in German].
Internistische Praxis 2005;45:159–62.
241. Vervaeren J. Rheumatoid arthritis: a new
treatment [in French]. J Pharm Belg 2002;
57(4):82–8.
137